The results presented in Figure 7B are very similar to the results obtained in A375 cells, suggesting that the enhanced cytotoxicity of the SB202190-thapsigargin drug combinations was not limited to BRAF-mutant cells, and thus did not depend on the type of oncogenic mutation driving the ERK MAPK pathway in melanoma cells. This evidence concerns the gene BRAF and melanoma.